From the results of existing clinical investigations in GC, the efficacy of PI3K inhibitors, AKT inhibitors, mTOR inhibitors, and other monotherapy were not as effective as dual PI3K/mTOR inhibitors or several combination therapies,195 suggesting that the restriction on the therapeutic effect by the heterogeneity of GC should be emphasized in designing new targeted medication regimens. This evidence concerns the gene AKT1 and gastric cancer.